By: Gillian McGovern From: .pharmacytimes.com Key Takeaways Expanded guidelines cover genetic/familial high-risk assessment for breast, ovarian, pancreatic, and prostate cancers, incorporating the latest research and expert recommendations. Guidelines detail when genetic testing is recommended, the type of testing, and management strategies for hereditary cancer risks, including screening and prevention. Emphasis is placed on genetic testing’s role in cancer care, enhancing …
ADCs Demonstrate Superiority Vs Chemotherapy in Recurrent Breast Cancer
By: Targeted Oncology Staff From: targetedonc.com Targeted Oncology: For patients with hormone receptor (HR)-positive, HER2-negative or HER2-low breast cancer, what do you use in later lines of therapy? Reshma Mahtani, DO: For patients in the second line who have HR-positive, HER2-low disease, the recommendation is for trastuzumab deruxtecan [Enhertu; T-DXd]. In patients who are not a candidate for T-DXd, the …
NCCN Updates Breast Cancer Guidelines to Include Goserelin
By: Jordyn Sava From: targetedonc.com Goserelin (Zoladex) has been included in the National Comprehensive Cancer Network (NCCN) Breast Cancer Panel at 2 dosing schedules, 3.6 mg every 4 weeks and 10.8 mg every 12 weeks, as a method for ovarian function suppression in Version 1.2024 of the breast cancer guidelines.1 As an injectable luteinizing hormone-releasing hormone agonist, goserelin is used …
Dr Wander on Using Platinum Chemotherapy Wisely in Breast Cancer
From: onclive.com Seth Wander, MD, PhD, medical oncologist, Massachusetts General Hospital; instructor, medicine, Harvard Medical School, discusses challenges related to the ongoing platinum chemotherapy shortage for patients with breast cancer and other malignancies, as well as ways that oncologists and cancer centers can operate during the shortage to continue to provide appropriate care for patients. In June 2023, the National …
NCCN Guidelines Add Neratinib for Patients With Breast Cancer
By: Jordyn Sava From: targetedonc Neratinib (Nerlynx) has been added to the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology for patients with breast cancer.1 These updated NCCN guidelines recommend neratinib with or without fulvestrant (Faslodex) or trastuzumab (Herceptin) and fulvestrant for patients with estrogen receptor (ER)-positive/HER2-negative or ER-negative/HER2-negative metastatic stage IV breast cancer and activating mutations in …
Cancer Screening Gaps Highlight Urgent Need to Address Health Inequities, According to NCCN Policy Summit
National Comprehensive Cancer Network’s #NCCNPolicy Summit, featuring White House Moonshot Coordinator and representatives from CDC, NCI, and USPSTF, examines critical need for improvements in cancer prevention and early detection across the United States. Today, the National Comprehensive Cancer Network® (NCCN®) hosted a policy summit to examine practice changes and trends in legislative and regulatory efforts that affect patient access to …
Clarifying Expert Recommendations for Breast Cancer Screening
From: nccn.org The National Comprehensive Cancer Network® (NCCN®) has published new NCCN Guidelines for Patients®: Breast Cancer Screening and Diagnosis to help people understand their personal risk for breast cancer, when they should begin screening, and how often to screen—in order to detect cancer earlier, for more treatment options and better outcomes. With this information, they are equipped to have more …
NCCN Now Recommends Breast Cancer Index for Predicting Benefit from Extended Endocrine Therapy
By: Audrey Sternberg From: cancernetwork.com The Breast Cancer Index assay is the only of its kind to be recommended in the National Comprehensive Cancer Network Guidelines for the treatment of breast cancer as being predictive of extended adjuvant endocrine therapy. Breast Cancer Index (BCI), a molecular gene expression–based test used for determining which patients with early-stage, hormone receptor (HR)–positive breast …
New Pediatric Cancer Guidelines Published by National Comprehensive Cancer Network Focus on Improving Long-Term Outcomes Worldwide
New NCCN Guidelines for Pediatric Aggressive Mature B-Cell Lymphomas address best practices for treating children with common and curable forms of non-Hodgkin lymphoma Today, the National Comprehensive Cancer Network® (NCCN®) published new guidelines for treating children, adolescents and young adults with pediatric aggressive mature B-cell lymphomas, including Burkitt lymphoma and diffuse large B-cell lymphoma. NCCN published the first pediatric NCCN …
Patient Priorities Should be Paramount when Measuring Quality in Cancer Care According to Panelists at NCCN Policy Summit
From: www.nccn.org The National Comprehensive Cancer Network® (NCCN®) hosted a policy summit at the National Press Club in Washington, DC, today, addressing how to define, measure, and apply quality in cancer care. Speakers across the cancer care continuum shared perspectives on current quality measurement initiatives including the Oncology Care Model and the Merit-based Incentive Payment System (MIPS), and looked ahead …